Hypoxia-inducible factor 1-alpha mRNA (HIF1A mRNA)

Hypoxia-inducible factor 1-alpha (HIF1A) mRNA is the messenger RNA transcript that encodes the alpha subunit of the HIF-1 transcription factor, a master regulator of the cellular response to low oxygen levels (Wang et al., 1995, PMID: 7545937). Under normoxic conditions, the HIF-1-alpha protein is rapidly degraded, but under hypoxic conditions, it stabilizes and translocates to the nucleus to activate genes involved in angiogenesis, glucose metabolism, and cell survival (UniProt Q16665). In many solid tumors, HIF1A mRNA is highly expressed or the protein is stabilized, driving tumor growth, metastasis, and resistance to therapy (Semenza, 2012, PMID: 22817877). Targeting the mRNA directly using antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs) aims to prevent the synthesis of the HIF-1-alpha protein entirely, thereby inhibiting downstream oncogenic signaling pathways. Clinical candidates like EZN-2968, a locked nucleic acid ASO, have demonstrated the feasibility of reducing HIF-1-alpha levels in patients by triggering mRNA degradation (Greenberger et al., 2008, PMID: 18413634). Additionally, RNAi-based approaches such as SYL040012 have been explored for ocular conditions like glaucoma to reduce hypoxia-induced damage (Martinez et al., 2014, PMID: 24474271). While promising, these therapies face challenges regarding systemic delivery and the potential for interfering with normal physiological responses to hypoxia, such as wound healing.

Other names

HIF-1-alpha mRNAHypoxia-inducible factor 1 subunit alpha mRNAHIF1A transcript

Antisense oligonucleotide-mediated degradation of mRNA via RNase H activation or RNA interference (RNAi) to prevent the translation of the HIF-1-alpha protein.